XML 101 R86.htm IDEA: XBRL DOCUMENT v3.10.0.1
(Restricted Stock and SARS Information) (Details) - USD ($)
$ in Thousands
12 Months Ended
Aug. 31, 2018
Aug. 31, 2017
Aug. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]      
Intrinsic value of SARS exercised $ 909 $ 5,053 $ 506
Fair value of restricted stock vested 62,592 44,010 34,857
Tax benefit (expense) for stock compensation expense 1,122 $ 560 $ 991
Unrecognized stock-based compensation expense — restricted stock $ 41,940    
Remaining weighted-average period for restricted stock expense 1 year 4 months 24 days